A clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our nitial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Lead Underwriter
Cowen and Company, LLC, Evercore Group L.L.C, SVB Securities LLC
